Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06126016 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 12, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 2 versions Re-verified since Dec 3, 2023, no change to tracked fieldsv2-v3
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
Trial Details
NCT Number NCT06126016
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov